503a Bulk List Guidance from the FDA
The FDA issued a guidance on May 24, 2019, in response to questions about a final rule from February 2019 on bulk drug substances that can be used to compound drugs under 503a of the federal Food, Drug and Cosmetic Act. The rule placed six substances on the bulks list for 503a facilities and excluded four others.
The newest guidance provides answers to questions about the list from February and what to do if you receive a prescription for or want to use one of the four bulk drug substances not included in the final rule: oxitriptan, piracetam, silver protein mild, and tranilast.
Download the FDA’s full guidance document >
One of the substances excluded from the February rule was oral oxitriptan for depression or insomnia – after several pharmacies and physicians contacted the FDA about compounding oral drugs with oxitriptan for tetrahydrobiopterin (BH4) deficiency, the FDA released a statement saying it does not object to oral oxitriptan for patients with BH4 deficiency.
Compounders are invited to respond to the FDA’s latest guidance document
Your comments are important
The FDA needs to hear from compounders – for more information on how to respond to the FDA’s rule, review their guidance document. You can also join with others in the compounding industry and provide your comments to the IACP (International Academy of Compounding Pharmacists).
Latest Articles
-
Posted: July 08, 2020Categories: Industry NewsRead more »
The Alliance for Pharmacy Compounding held their Advocacy Town Hall, which you can watch in its entirety...
-
Posted: June 25, 2020Categories: Industry NewsRead more »
A recent clinical trial from the UK showed decreased mortality for patients seriously ill with COVID-19 requiring oxygen or ventilators when treatment included the corticosteroid dexamethasone...
-
Posted: June 05, 2020Categories: Industry NewsRead more »
This week, two major medical journals retracted separate studies on Covid-19 treatments due to an inability to validate the data and methodology used in the studies.
-
Posted: May 29, 2020Categories: Compounding EducationRead more »
The Institute for Safe Medication Practices (ISMP) recently shared a medication error involving remdesivir vial labels that provides an important example for compounders...
-
Posted: May 14, 2020Categories: Compounding EducationRead more »
Change control SOPs are critical in sterile compounding - and pharmacy technicians are not the only ones who need to understand machines and tools in the lab and workflows.
-
Posted: May 11, 2020Categories: Compounding EducationRead more »
Formulations require different sample amounts to allow for an accurate result representative of the compounded preparation.
-
Posted: April 21, 2020Categories: Industry NewsRead more »
Covid-19 has led to a constantly changing regulatory environment to support patient care. But pharmacists need to take care to monitor national as well as state laws and guidelines.
-
Posted: April 17, 2020Categories: Compounding EducationRead more »
Download our one-page flyer with tips and resources to help support the service your pharmacy and staff are providing to your communities.
